Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
Conditions
Alcohol Dependence | Stress Disorders, Post-Traumatic
What is the purpose of this trial?
Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence.
The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD.
Participation Guidelines
- Age:
- 21 Years - 65 Years
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Elizabeth Ralevski
- Dates:
- January 2009
- Last Updated:
- January 26, 2012
- Study HIC#:
- 0801003450
Clinicaltrials.gov ID: NCT00744055
For more information about this trial, contact:
Melanie Russo
203-932-5711 ext 5667
melanie.russo@yale.edu
Investigator
Ismene Petrakis, MD
Principal Investigator
